Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parasitic Diseases Clear all
Terminated Phase 2 Interventional

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

NCT00291057
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 24 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 23, 2026, 7:15 PM EDT
Completed No phase listed Observational

Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria

NCT01228344
View directory record Official record
Conditions
Malaria
Interventions
Artemether-lumefantrine
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

NCT01169077
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Placebo, EP-1300
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Not applicable Interventional

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NCT00000666
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1

NCT02898779
View directory record Official record
Conditions
Malaria
Interventions
Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oxford, Mississippi
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

NCT00545168
View directory record Official record
Conditions
Pediculus Capitis Infestation
Interventions
Spinosad, Permethrin 1%
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Ormond Beach, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs

NCT05666778
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions
Menstrual Cup
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

NCT02658435
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 150 mg, Matched placebo 150mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Glendale, California • Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

NCT00002248
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Drug
Lead sponsor
Univax Biologics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 7:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Sodium Stibogluconate Treatment of Leishmaniasis

NCT00662012
View directory record Official record
Conditions
Leishmaniasis
Interventions
Sodium Stibogluconate (SSG)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Moxidectin in Adults With Scabies

NCT05875441
View directory record Official record
Conditions
Scabies
Interventions
Moxidectin Oral Product, Placebo
Drug
Lead sponsor
Medicines Development for Global Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea

NCT04969913
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults

NCT02013687
View directory record Official record
Conditions
Malaria
Interventions
Pfs25 VLP- FhCMB
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

NCT00075049
View directory record Official record
Conditions
Malaria
Interventions
RTS,S with AS02A/AS01B adjuvant
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

NCT03672487
View directory record Official record
Conditions
Chagas Disease
Interventions
Benznidazole, Placebo Oral Tablet
Drug
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
13 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India

NCT01629771
View directory record Official record
Conditions
Lymphatic Filariasis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 23, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections

NCT00004996
View directory record Official record
Conditions
Healthy, Helminthiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 4 Interventional

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

NCT01641341
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Bifidobacterium infantis, Pancrelipase, Nitazoxanide, Placebo
Drug
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 23, 2026, 7:15 PM EDT
Not yet recruiting No phase listed Observational

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

NCT05477953
View directory record Official record
Conditions
Chagas Disease
Interventions
Nifurtimox (BAYA2502)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Multiple Locations, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

NCT04072302
View directory record Official record
Conditions
Malaria
Interventions
KAF156, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Factors Involved in Resistance to Severe Malaria

NCT00368810
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 7:15 PM EDT